Last reviewed · How we verify

Pariet

Eisai Korea Inc. · FDA-approved active Small molecule ✓ Verified May 2026

Pariet is a Small molecule drug developed by Eisai Korea Inc.. It is currently FDA-approved. Also known as: Rabeprazole Sodium, Rabeprazole.

Pariet, also known as rabeprazole sodium, is a small molecule medication used to treat conditions such as peptic ulcer disease, gastroesophageal reflux disease, and Helicobacter pylori infection. It works by decreasing stomach acid production.

At a glance

Generic namePariet
Also known asRabeprazole Sodium, Rabeprazole
SponsorEisai Korea Inc.
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Pariet

What is Pariet?

Pariet is a Small molecule drug developed by Eisai Korea Inc..

Who makes Pariet?

Pariet is developed and marketed by Eisai Korea Inc. (see full Eisai Korea Inc. pipeline at /company/eisai-korea-inc).

Is Pariet also known as anything else?

Pariet is also known as Rabeprazole Sodium, Rabeprazole.

What development phase is Pariet in?

Pariet is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing